Advertisement
Screener

Caribou Biosciences, Inc. (CRBU) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

2.4 / 5 stars · 24/51 Roast Me

Caribou Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

Caribou Biosciences, Inc. (CRBU) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.

Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-03-05

  • Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2025-06-30 was 0.00%.
  • Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2025-03-31 was 0.00%.
  • Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-09-30 was 0.00%.
  • Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-06-30 was 0.00%.
  • Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
  • Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
  • Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
  • Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month
2025-12-310.00%
10-K · filed 2026-03-05
2025-06-300.00%
10-Q · filed 2025-08-12
0.00%
10-Q · filed 2025-08-12
2025-03-310.00%
10-Q · filed 2025-05-08
2024-12-310.00%
10-K · filed 2026-03-05
2024-09-300.00%
10-Q · filed 2024-11-06
0.00%
10-Q · filed 2024-11-06
2024-06-300.00%
10-Q · filed 2025-08-12
0.00%
10-Q · filed 2025-08-12
2024-03-310.00%
10-Q · filed 2025-05-08
2023-12-310.00%
10-K · filed 2025-03-10
2023-09-300.00%
10-Q · filed 2024-11-06
0.00%
10-Q · filed 2024-11-06
2023-06-300.00%
10-Q · filed 2024-08-06
0.00%
10-Q · filed 2024-08-06
2023-03-310.00%
10-Q · filed 2024-05-07
2022-12-310.00%
10-K · filed 2024-03-11
2022-09-300.00%
10-Q · filed 2023-11-07
0.00%
10-Q · filed 2023-11-07
2022-06-300.00%
10-Q · filed 2023-08-08
0.00%
10-Q · filed 2023-08-08
2022-03-310.00%
10-Q · filed 2023-05-09
2021-12-310.00%
10-K · filed 2023-03-09
2021-09-300.00%
10-Q · filed 2022-11-08
0.00%
10-Q · filed 2022-11-08
2021-06-300.00%
10-Q · filed 2022-08-09
0.00%
10-Q · filed 2022-08-09
2021-03-310.00%
10-Q · filed 2022-05-09
2020-12-310.00%
10-K · filed 2022-03-21
2020-09-300.00%
10-Q · filed 2021-11-09
2020-06-300.00%
10-Q · filed 2021-09-02
0.00%
10-Q · filed 2021-09-02
2019-12-310.00%
10-K · filed 2022-03-21

Similar stocks

Stock NameCountryMarket CapPE Ratio
Armata Pharmaceuticals, Inc. (ARMP)United States$0.132B
Neumora Therapeutics, Inc. (NMRA)United States$0.132B-1.48
enGene Therapeutics Inc. (ENGN)$0.129B-0.92
Tenaya Therapeutics, Inc. (TNYA)United States$0.140B-1.60
LENZ Therapeutics, Inc. (LENZ)United States$0.117B-1.41
Humacyte, Inc. (HUMA)United States$0.155B-2.26
Black Diamond Therapeutics, Inc. (BDTX)United States$0.109B-2.48
Outlook Therapeutics, Inc. (OTLK)United States$0.162B-4.90
Acumen Pharmaceuticals, Inc. (ABOS)United States$0.162B-1.83
Cardiff Oncology, Inc. (CRDF)United States$0.101B-2.22